AzTrials
AzTrials

Invasive Breast CancerPhase 3APTneoNCT03595592

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

A Phase 3 study testing Trastuzumab, Pertuzumab and Carboplatin in people with Invasive Breast Cancer, run by Fondazione Michelangelo at 65 sites in 4 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival (EFS) in regimens with and without atezolizumab. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Invasive Breast Cancer
What is being tested?
Trastuzumab, Pertuzumab and Carboplatin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
650 participants
Where
65 sitesin 4 countries
Study dates
7 Sep 2018to 15 Mar 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Female patients aged 18 years or older with early high-risk ((T1cN1; T2N1; T3N0) or locally advanced and inflammatory breast cancers (stage III A-C according to AJCC) suitable for neoadjuvant treatment
  • Histologically confirmed unilateral invasive breast cancer
  • HER2 positive disease according to ASCO/CAP guidelines 2013 [defined as IHC 3+ or ISH positive (by gene copy number or HER2 gene/CEP17 ratio of 2 or greater)]
  • Known estrogen (ER) and progesterone receptor (PgR)
  • Availability of a representative paraffin-embedded (FFPE) tumor block taken at diagnostic biopsy for central confirmation of HER2 eligibility, for assessment of ER, PgR, Ki67 and PD-L1 expression and for biomarker evaluation is mandatory. Note: the diagnostic biopsy of the breast lesion may have been taken before the required screening procedures. If diagnostic sentinel node biopsy if performed, an FFPE block must be available. An FFPE tumor block is also mandatory after the first cycle of therapy. Surgery tissue (residual tumor or tumor bed in case of pCR and axillary node material) is also mandatory.
  • Consent to the collection of blood samples mandatorily before starting neoadjuvant treatment, after the first cycle of therapy, at the end of neoadjuvant treatment (before surgery), 6 months after surgery and at the end of all treatments.
Show all 10Show fewer
  • ECOG performance status 0 or 1
  • For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of study drugs. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Examples of contraceptive methods with a failure rate of < 1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of < 1% per year. Barrier methods must always be supplemented with the use of a spermicide
  • Written informed consent to participate in the trial (approved by the Institutional Review Board [IRB]/ Independent Ethics Committee [IEC]) obtained prior to any study specific screening procedures
  • Willing and able to comply with the protocol

Who cannot join

  • Evidence of bilateral breast cancer or metastatic disease (M1)
  • Patients with HER2-negative defined as 0-1+ by immunohistochemistry or 2+ by immunohistochemistry without HER2 amplification by either In Situ Hybridization (ISH) or other amplification tests done locally are considered not eligible for the study
  • Pregnant or lactating women. Documentation of a negative pregnancy test must be available for premenopausal women with intact reproductive organs and for women less than one year after the last menstrual cycle
  • Women with childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception, for example abstinence, an intra-uterine device, or double barrier method of contraception
  • Previous treatment with chemotherapy, hormonal therapy or an investigational drug for any type of malignancy
  • Previous investigational treatment for any condition other than malignancy within 4 weeks of randomization date
Show all 38Show fewer
  • Administration of a live, attenuated vaccine within 4 weeks before Day 1 or anticipation that such a live attenuated vaccine will be required during the study
  • Previous or concomitant malignancy of any other type that could affect compliance with the protocol or interpretation of results. Patients with curatively treated basal cell carcinoma of the skin or in situ cervix cancer are generally eligible
  • Pre-existing motor or sensory neuropathy of grade > 1 for any reason
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
  • Patients with prior allogeneic stem cell or solid organ transplantation
  • History of autoimmune disease including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
  • History of idiopathic pulmonary fibrosis (including bronchiolitis obliterans with organizing pneumonia) or evidence of active pneumonitis on screening chest computed tomography scan
  • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, fatty liver, and inherited liver disease
  • History of HIV infection, active hepatitis B (chronic or acute), or hepatitis C infection. Patients with past or resolved hepatitis B infection (defined as having a negative HBsAg test and a positive hepatitis B core antigen [anti-HBc] test) are eligible.
  • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction assay (PCR) is negative for HCV RNA
  • Active tuberculosis
  • Severe infections within 4 weeks prior to Day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. Signs or symptoms of significant infection within 2 weeks prior to Day 1
  • Received oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1
  • Other serious illness or medical condition including: history of documented congestive cardiac failure; New York Heart Association (NYHA) Class II or greater CHF; angina pectoris requiring anti-anginal medication or unstable angina within 6 months prior to Day 1; evidence of transmural infarction on ECG; myocardial infarction stroke or transient ischemic attack (TIA) within 6 months prior to Day 1; poorly controlled hypertension (e.g. systolic >180 mm Hg or diastolic >100 mm Hg; however, patients with hypertension which is well controlled on medication are eligible); clinically significant valvular heart disease; high-risk uncontrolled arrhythmias
  • Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and precluding informed consent or adversely affecting compliance with study drugs
  • Serious uncontrolled infections (bacterial or viral) or poorly controlled diabetes mellitus
  • Any of the following abnormal baseline hematological values:
  • White blood count (WBC) < 2.5 x 109/L
  • Absolute Neutrophil Count (ANC) < 1.5 x 109/L
  • Lymphocyte count < 0.5 x 109/L
  • Platelet count < 100 x 109/L
  • Hemoglobin (Hb) < 10 g/dL
  • Any of the following abnormal baseline laboratory tests
  • Serum total bilirubin > 1.5 x ULN (upper limit of normal) (except for patients with clearly documented Gilbert's syndrome)
  • Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.25 x ULN
  • Alkaline phosphatase > 2.5xx ULN
  • Serum creatinine > 1.5 x ULN
  • INR and aPTT > 1.5 × ULN within 2 weeks prior to enrollment. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.
  • Baseline left ventricular ejection fraction (LVEF) < 50% by echocardiography or multi-gated scintigraphic scan (MUGA)
  • Major surgical procedure within 28 days prior to Day 1 or anticipation of need for a major surgical procedure during the course of the study
  • Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to Day 1 or at any time during the study.

Trial locations and contacts

65 sites in 4 countries.

65 sites in 4 countries

Spain27 sites

  • Centro Oncologico de Galicia

    A Coruña, 15009

  • Hospital Virgen de Los Lirios

    Alcoy, 03804

  • Hospital General Unv. Alicante

    Alicante, 03010

  • "Hospital Infanta Cristina de Badajoz (CICAB - Centro de Investigación Clínica del Área de Salud de Badajoz)"

    Badajoz, 06007

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08025

  • Hospital Clinic Provincial

    Barcelona, 08036

  • Hospital del Mar - IMAS

    Barcelona, Hospital del Mar - IMAS

  • Hospital de Basurto

    Bilbao, 48013

  • Hospital San Pedro de Alcantara

    Cáceres, 10003

  • Hospital Virgen de la Nieves

    Granada, 18012

  • Hospital Juan Ramón Jimenez

    Huelva, 21005

  • Hospital Gregorio Marañon

    Madrid, 28007

  • MD Anderson Cancer Center

    Madrid, 28033

  • Hospital Clinico San Carlos

    Madrid, 28040

  • Hospital Unv. Fundación Jimenez Diaz

    Madrid, 28040

  • Hospital de Fuenlabrada

    Madrid, 28942

  • Complejo Hospitalario de Especialidades Virgen de la Victoria

    Málaga, 29010

  • Hospital General Universitario Morales Meseguer

    Murcia, 30008

  • Clinica Universitaria de Navarra

    Pamplona, 31008

  • Complejo Hospitalario de Salamanca

    Salamanca, 37007

  • Hospital de Donostia

    San Sebastián, 20014

  • Hospital Onkologikoa

    San Sebastián, 20014

  • Hospital Clinico Unv. de Santiago

    Santiago de Compostela, 15706

  • Hospital Virgen de la Salud de Toledo

    Toledo, 45004

  • Hospital Clínico Universitario de Valencia

    Valencia, 46010

  • Hospital Lozano Blesa

    Zaragoza, 50009

  • Hospital Miguel Servet

    Zaragoza, 50009

Other trials in Spain

Germany17 sites

  • Klinik für Gynäkologie am Campus Charité Mitte (CCM)

    Berlin, 10113

  • Department of Gynecology and Obstetrics, Marienhospital

    Bottrop, 46236

  • Klinikum Coburg, Frauenklinik

    Coburg, 96450

  • St Johannes Hospital

    Dortmund, 44137

  • Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe - Universitätsklinikum Carl Gustav Carus

    Dresden, 01307

  • Markus Krankenhaus - Klinik für Gynäkologie und Geburtshilfe

    Frankfurt, 60431

  • SRH Waldklinikum

    Gera, 07548

  • Universitätsklinikum Greifswald, Frauenklinik

    Greifswald, 17475

  • Klinik und Poliklinik für Gynäkologie am Universitätsklinikum (Saale)

    Halle, 06120

  • Gynäkologisch-Onkologische Praxis

    Hanover, 30177

  • NCT Nationales Zentrum für Tumorerkrankungen Gynäkologische Onkologie, Frauenklinik

    Heidelberg, 69120

  • St. Marien-Klinik GmbH Frauenklinik der St. Vincentius-Kliniken gAG - Gynäkologisches Krebszentrum Karlsruhe - Brustzentrum Karlsruhe

    Karlsruhe, 76135

  • Städtisches Klinikum Magdeburg - Klinik für Allgemein - und Viszeralchirurgie

    Magdeburg, 39130

  • Am Schillerhain 1-8

    Marktredwitz, 95615

  • Klinikum Nürnberg Nord

    Nuremberg, 90419

  • Onkologische Praxis Velbert

    Velbert, 42551

  • Marien Hospital Witten

    Witten, 58452

Other trials in Germany

Italy17 sites

  • Ospedale Papa Giovanni XXIII

    Bergamo, 24128

  • Presidio Ospedaliero Di Summa-Perrino

    Brindisi, 72100

  • Dipartimento di Oncologia Medica AUSL della Romagna

    Faenza, 48018

  • IST San Martino

    Genova, 16132

  • Istituto Scientifico Romagnolo per lo studio e la cura dei tumori

    Meldola, 47014

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, 20133

  • Istituto Europeo di Oncologia

    Milan, 20141

  • Ospedale Luigi Sacco

    Milan, 20160

  • Ospedale San Raffaele

    Milan

  • AO Universitaria Policlinico di Modena

    Modena, 41124

  • Ospedale Sacro Cuore - Don Calabria

    Negrar, 37024

  • Fondazione Salvatore Maugeri

    Pavia, 27100

  • Azienda Ospedaliero Universitaria Pisana Ospedale S. Chiara

    Pisa, 56100

  • Arcispedale Santa Maria Nuova - A.O. Reggio Emilia

    Reggio Emilia, 42123

  • Ospedale Infermi AUSL della Romagna

    Rimini, 247900

  • Istituto Nazionale Tumori - Regina Elena

    Roma, 00144

  • Ospedale Santa Maria della Misericordia

    Udine, 33100

Other trials in Italy

Austria4 sites

  • Klinikum Klagenfurt am Wörthersee Abteilung für Innede Medizin und Hämatologie und internistische Onkologie

    Klagenfurt, 9020

  • Krankenhaus der Barmherzigen Schwestern

    Linz, 4010

  • Universitätsklinikum St. Pölten Klinische Abteilung für Innere Medizin

    Sankt Pölten, 3100

  • Klinische Abteilung für Allgemeine Gynäkologie und Gynäkologische Onkologie - Universitätsklinik für Frauenheilkunde Medizinische Universität Wien / AKH "

    Vienna, 1090

Other trials in Austria

About this study

Official title: Atezolizumab, Pertuzumab and Trastuzumab With Chemotherapy as Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)

n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival (EFS) in regimens with and without atezolizumab. Following the neoadjuvant part of the study, after surgery all patients will continue to receive trastuzumab and pertuzumab to complete one year of anti-HER2 therapy. Similarly, patients allocated to receive atezolizumab will continue atezolizumab to complete one year In addition, several IHC and molecular assays will be performed before and during the period of chemotherapy administration and at surgery with the goal of defining a marker of efficacy to be later validated in a larger adjuvant setting.

Read the detailed description

Dual targeting of HER2 with trastuzumab and pertuzumab in HER2-positive breast cancer is linked to clinical evidence of reversal of initial resistance to trastuzumab (Baselga J et al, J Clin Oncol 2010) in cases progressing on trastuzumab therapy, and in dramatic improvement in progression free and overall survival when the two monoclonal antibodies are used in combination with docetaxel (THP regimen) as first line therapy of metastatic disease as shown in the CLEOPATRA study (Swain S et al, ESMO abstract 2014). The randomized NeoSphere study showed that the same THP regimen given for 4 cycles as neoadjuvant treatment increased the rate of pathologic complete response (pCR) over that with conventional docetaxel and trastuzumab or docetaxel and pertuzumab (Gianni L et al, Lancet Oncol 2012).

Encouraging clinical data emerging in the field of tumor immunotherapy have demonstrated that therapies focused on enhancing T cell responses against cancer can result in a significant survival benefit in patients with advanced malignancies (Hodi FS and Dranoff G, J Cutan Pathol 2010; Kantoff PW et al, New Engl J Med 2010; Chen DS et al, Clin Cancer Res 2012). Many human tumors have been found to overexpress PD L1, which acts to suppress anti tumor immunity. PD 1 is an inhibitory receptor expressed on T cells following T cell activation, which is sustained in states of chronic stimulation, such as in chronic infection or canc Atezolizumab is a human monoclonal antibody containing an engineered Fc-domain to optimize efficacy and safety that targets PD-L1 and blocks binding of its receptors, including PD-1 and B7.1.

In addition to being involved in the natural progression of cancer, immunity can affect the activity of various anticancer agents. Accordingly, recent evidence suggests that some chemotherapeutic drugs, such as anthracyclines and oxaliplatin, rely on the induction of anticancer immune responses. Immune responses also play a major role in the efficacy of targeted therapies with monoclonal antibodies (Stagg J et al, Breast Care 2012). Studies have shown monoclonal antibodies such as trastuzumab and rituximab rely in part on immunemediated killing through antibody-dependent cellular cytotoxicity (ADCC). While innate immune responses appear to be important for tumor antigen-targeted monoclonal antibody therapies, recent studies in mice and correlative clinical evidence suggest that trastuzumab may also stimulate adaptive antitumor immunity. These studies raise the possibility that combination strategies may be used to capitalize on the adaptive tumor-specific immunity generated by anti-HER2 monoclonal antibodies.

Based on these considerations, we plan to conduct a randomized neoadjuvant study of the combination of trastuzumab, pertuzumab, carboplatin and paclitaxel with or without atezolizumab in women with early high-risk and locally advanced HER2-positive suitable for neoadjuvant therapy. One study arm will also include anthracycline and cyclophosphamide.

Keywords
Unilateral, HER2 positive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TrastuzumabDrug

    Also called Herceptin

    Trastuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab

  • PertuzumabDrug

    Also called Perjeta

    Pertuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab

  • CarboplatinDrug

    Also called Carboplatin Hospiria

    Carboplatin will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab

  • PaclitaxelDrug

    Also called Paclitaxel Hospiria

    Paclitaxel will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab

  • DoxorubicinDrug

    Also called Doxorubicin Pfizer

    Adriamycin will be delivered i.v. on day 1 every 3 weeks in arm ACy followed by HPCT for the first 3 cycles

  • CyclophosphamideDrug

    Also called Cyclophosphamide Sandoz

    Cyclophosphamide will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab for the first 3 cycles

  • AtezolizumabDrug

    Also called Tecentriq

    Atezolizumab will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab

  • SurgeryProcedure or surgery

    Breast cancer surgery (breast and axilla) either conservative or radical not later than 4 weeks from the last dose of neoadjuvant therapy in all study arms

Study groups in NCT03595592
Study groupRoleWhat they receive
HPCTActive comparatorPatients will receive a combination of trastuzumab, pertuzumab, carboplatin and paclitaxel as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8. Paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 12 additional cycles as adjuvant therapy.
Receives: Drug: Trastuzumab; Drug: Pertuzumab; Drug: Carboplatin; Drug: Paclitaxel; Procedure: Surgery
ACy followed by HPCT and atezolizumabExperimentalPatients will receive a combination of doxorubicin (A, 60 mg/m2 i.v.), cyclophosphamide (C, 600 mg/m2 i.v.) and atezolizumab (1200 mg i.v.) on day 1 every 3 week for 3 cycles. Subsequently they will be given trastuzumab on day 1 (H, at the loading dose of 8 mg/kg i.v. then 6 mg/kg i.v.), pertuzumab on day 1 (P, at the loading dose of 840 mg .v., then 420 mg i.v.), carboplatin (C) at AUC 2 i.v. on day 1 and day 8, paclitaxel (T) at 90 mg/m2 i.v. on day 1 and day 8, and atezolizumab 1200 mg i.v. on day 1 for 3 cycles every 3 weeks. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab and pertuzumab will then be delivered for 15 additional cycles and atezolizumab for 12 additional cycles as adjuvant therapy.
Receives: Drug: Trastuzumab; Drug: Pertuzumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Atezolizumab; Procedure: Surgery
HPCT and atezolizumabExperimentalPatients will receive a combination of trastuzumab, pertuzumab, carboplatin, paclitaxel and atezolizumab as neoadjuvant therapy for 6 cycles every 3 weeks. Trastuzumab (H) will be delivered on day 1 at the dose of 8 mg/kg loading dose i.v., then 6 mg/kg i.v. Pertuzumab (P) will be delivered on day 1 at the dose of 840 mg loading dose i.v., then 420 mg i.v. Carboplatin (C) will be administered at AUC 2 i.v. on day 1 and day 8; paclitaxel (T) will be given at 90 mg/m2 i.v. on day 1 and day 8; atezolizumab at the dose of 1200 mg i.v. on day 1. Definite surgery will be performed not later than 4 weeks after the last dose of neoadjuvant therapy. Trastuzumab, pertuzumab and atezolizumab will then be delivered for 12 additional cycles as adjuvant therapy.
Receives: Drug: Trastuzumab; Drug: Pertuzumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Atezolizumab; Procedure: Surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Event Free Survival (EFS)

    Assess EFS (disease progression while on neoadjuvant therapy or disease recurrence after surgery) in the study arms

    Measured: 5 years after the randomization of the last patient

Secondary outcomes (5)

  1. Pathological complete response (pCR)

    Assess the rate of pCR defined as absence of invasive cancer in both breast and axillary nodes (ypT0Tis ypN0)

    Measured: At surgery, an expected average of 26 weeks after the randomization of the last patients

  2. Clinical objective response

    Assess the rate of clinical response rate after neoadjuvant therapy

    Measured: Participants will be followed for the duration of neoadjuvant therapy, an expected average of 22 weeks

  3. Distant Event Free Survival (DEFS)

    Assess DEFS (defined as the occurrence of distant disease progression while on neoadjuvant therapy or distant disease recurrence after surgery) in the study arms

    Measured: 5 years after the randomization of the last patients

  4. Overall Survival (OS)

    Assess OS in all arms

    Measured: 5 years after the randomization of the last patient

  5. Number of participants with adverse events as a measure of safety and tolerability

    Number of participants with adverse events and related grades in all arms

    Measured: Participants will be followed for up to 5 years from the last randomized patient

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2018
  2. Study start7 Sep 2018
  3. Primary completion15 Dec 2026 (estimated)
  4. Study completion15 Mar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Parallel randomization to the study arms
Masking
None (open label)
Enrolment
650 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03595592
Sponsor's protocol ID
FM-17-B01
Other IDs
2017-000981-31, 2017
Acronym
APTneo
Status last verified
Mar 2024
First submitted
11 Jul 2018
Last updated
6 Mar 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Trastuzumab, Pertuzumab and Carboplatin in people with Invasive Breast Cancer, run by Fondazione Michelangelo at 65 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 38 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 6 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 65 sites in Spain, Germany, Italy, Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Event Free Survival (EFS) (time frame: 5 years after the randomization of the last patient). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03595592.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2024; AzTrials last refreshed its copy on 8 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in